我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

再发性心肌梗死二级预防中药物治疗的研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第6期
页码:
740-742
栏目:
综述
出版日期:
2015-07-15

文章信息/Info

Title:
Research progress of pharmacological therapy in secondary prevention of recurrent myocardial infarction
作者:
潘 刚1; 张卫泽1; 支延春2
(1.兰州军区兰州总医院心内科，甘肃 兰州 730050；
2.兰州大学第二医院心内科，甘肃 兰州730030)
Author(s):
PAN Gang1;  ZHANG Wei-ze1;  ZHI Yan-chun2
(1.Department of Cardiology, PLA General Hospital, Lanzhou Military Area Command, Lanzhou 730050, Gansu, China；
2.Second Clinical Medical Academy, Lanzhou University, Lanzhou 730030, Gansu, China)
关键词:
心肌梗死; 再发性; 二级预防; 药物
Keywords:
myocardial fraction;  recurrent;  secondary prevention;  medicine
分类号:
R542.22
DOI:
-
文献标识码:
A
摘要:
近年来对再发性心肌梗死（RMI）二级预防的研究不断增多，本文将以经典的临床指南为基础，汇总近年来二级预防药物的相关理论研究与临床观察的新成果，并对其临床意义和不足之处试做评述，以此希望对临床实践和科学研究有所帮助。
Abstract:
In recent years, more and more research has been conducted in the secondary prevention of recurrent myocardial infarction. This article, based on classic guidelines, will review some new theoretical findings and clinical observations from the perspective of pharmacological therapy and provide some preliminary comments on their clinical significance as well as inadequacies.

参考文献/References

[1]Shotan A,Blondheim DS,Gottlieb SA,et al.Comparison of outcome of recurrent versus first ST-Segment elevation myocardial infarction(from National Israel surveys 1998 to 2006)[J].Am J Cardiol,2011,107(12):1730-1737.
[2]Roger VL,Go AS,Lloyd-Jones DM,et al.Heart disease and stroke statistics--2011 update:a report from the American Heart Association[J].Circulation,2011,123(4):e18-e209.
[3]卢 兵.药物在心肌梗死二级预防中的应用[J].中国医药指南,2010,8(14):150-151.
[4]Yi X,Zhou Q,Lin J,et al.Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events[J].Int J Stroke,2013,8(7):535-539.
[5]Krasopoulos G,Brister SJ,Beattie WS,et al.Aspirin“resistance”and risk of cardiovascular morbidity: systematic review and meta-analysis[J].BMJ,2008,336(7637):195-198.
[6]Sorensen R,Abildstrom SZ,Weeke P,et al.Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention:a cohort study[J].BMC Cardiovasc Disord, 2010,10:6.
[7]Kohli P,Wallentin L,Reyes E,et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the Plato study[J].Circulation,2013,127(6):673-680.
[8]Fragoulakis V,Kourlaba G,Maniadakis N,et al.Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece[J].Clinicoecon Outcomes Res,2012,4:135-143.
[9]Huang WC,Lin TW,Chiou KR,et al.The effect of intensified low density lipoprotein cholesterol reduction on recurrent myocardial infarction and cardiovascular mortality[J].Acta Cardiologica Sinica,2013,29(5):404-412.
[10]Van De Woestijne AP,Wassink AJ,Monajemi H,et al.Plasma triglyceride levels increase the risk for recurrent vascular events Independent of LDL-cholesterol or nonHDL-cholesterol[J].Int J Cardiol,2013,167(2):403-408.
[11]Miller M,Cannon CP,Murphy SA,et al.Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial[J].J Am Coll Cardiol,2008,51(7):724-730.
[12]Van De Woestijne AP,Van Der Graaf Y,Liem AH,et al.Low High-Density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive Lipid-Lowering medication[J].J Am Coll Cardiol,2013,62(20):1834-1841.
[13]胡大一,王家宏.我国血脂异常防治现状[J].中国实用内科杂志,2009,29(1):2-4.
[14]Murphy SA,Cannon CP,Wiviott SD,et al.Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22(Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22)trial[J].J Am Coll Cardiol,2009,54(25):2358-2362.
[15]易远明.氯吡格雷联用辛伐他汀对急性心肌梗死再发的预防[J].中国老年学杂志,2013,33(9):2018-2020.
[16]Cannon CP,Cannon PJ.Physiology COX-2 inhibitors and cardiovascular risk[J].Science,2012,336(6087):1386-1387.
[17]Olsen A,Fosbol EL,Lindhardsen J,et al.Duration of treatment with nonsteroidal Anti-Inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction a nationwide cohort study[J].Circulation,2011,123(20):2226-2235.
[18]Trelle S,Reichenbanch S,Wandel S,et al.Cardiovascular safety of non-steroidal anti-inflammatory drugs:Network meta-analysis[J].BMJ,2011,342:c7086.

备注/Memo

备注/Memo:
收稿日期：2014-10-09.
基金项目：全军医药卫生科研基金项目资助（CLZ2J014）
通讯作者：张卫泽，主任医师，主要从事冠心病的基础与临床研究 Email:zhangzwz@medmail.com.cn
作者简介：潘刚，硕士生 Email：pangangforever@163.com
更新日期/Last Update: 2015-07-23